These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 31230825)
1. Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. Greene SJ; Felker GM; Giczewska A; Kalogeropoulos AP; Ambrosy AP; Chakraborty H; DeVore AD; Fudim M; McNulty SE; Mentz RJ; Vaduganathan M; Hernandez AF; Butler J Can J Cardiol; 2019 Sep; 35(9):1097-1105. PubMed ID: 31230825 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. Butler J; Anstrom KJ; Felker GM; Givertz MM; Kalogeropoulos AP; Konstam MA; Mann DL; Margulies KB; McNulty SE; Mentz RJ; Redfield MM; Tang WHW; Whellan DJ; Shah M; Desvigne-Nickens P; Hernandez AF; Braunwald E; JAMA Cardiol; 2017 Sep; 2(9):950-958. PubMed ID: 28700781 [TBL] [Abstract][Full Text] [Related]
3. Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. Butler J; Hernandez AF; Anstrom KJ; Kalogeropoulos A; Redfield MM; Konstam MA; Tang WH; Felker GM; Shah MR; Braunwald E JACC Heart Fail; 2016 Sep; 4(9):726-35. PubMed ID: 27522631 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease. Beldhuis IE; Myhre PL; Claggett B; Damman K; Fang JC; Lewis EF; O'Meara E; Pitt B; Shah SJ; Voors AA; Pfeffer MA; Solomon SD; Desai AS JACC Heart Fail; 2019 Jan; 7(1):25-32. PubMed ID: 30606484 [TBL] [Abstract][Full Text] [Related]
5. Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. Beldhuis IE; Myhre PL; Bristow M; Claggett B; Damman K; Fang JC; Fleg JL; McKinlay S; Lewis EF; O'Meara E; Pitt B; Shah SJ; Vardeny O; Voors AA; Pfeffer MA; Solomon SD; Desai AS J Am Coll Cardiol; 2021 Mar; 77(9):1211-1221. PubMed ID: 33663739 [TBL] [Abstract][Full Text] [Related]
6. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial. Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411 [TBL] [Abstract][Full Text] [Related]
7. Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). Vardeny O; Wu DH; Desai A; Rossignol P; Zannad F; Pitt B; Solomon SD; J Am Coll Cardiol; 2012 Nov; 60(20):2082-9. PubMed ID: 23083787 [TBL] [Abstract][Full Text] [Related]
8. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine? Ahmed A J Am Geriatr Soc; 2002 Jul; 50(7):1297-300. PubMed ID: 12133029 [TBL] [Abstract][Full Text] [Related]
9. Worsening Renal Function during Management for Chronic Heart Failure with Reduced Ejection Fraction: Results From the Pro-BNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. Ibrahim NE; Gaggin HK; Rabideau DJ; Gandhi PU; Mallick A; Januzzi JL J Card Fail; 2017 Feb; 23(2):121-130. PubMed ID: 27469482 [TBL] [Abstract][Full Text] [Related]
10. Renal function and natriuresis-guided diuretic therapy - a pre-specified analysis from the PUSH-AHF trial. Damman K; Beldhuis IE; van der Meer P; Krikken JA; Coster JE; Nieuwland W; van Veldhuisen DJ; Voors AA; Ter Maaten JM Eur J Heart Fail; 2024 Jun; 26(6):1347-1357. PubMed ID: 38734982 [TBL] [Abstract][Full Text] [Related]
11. Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study. Myhre PL; Vaduganathan M; O'Meara E; Claggett BL; de Denus S; Jarolim P; Anand IS; Pitt B; Rouleau JL; Solomon SD; Pfeffer MA; Desai AS Circ Heart Fail; 2020 Jan; 13(1):e006638. PubMed ID: 31957468 [TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B; J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881 [TBL] [Abstract][Full Text] [Related]
13. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Rossignol P; Dobre D; McMurray JJ; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Messig M; Vincent J; Girerd N; Bakris G; Pitt B; Zannad F Circ Heart Fail; 2014 Jan; 7(1):51-8. PubMed ID: 24297687 [TBL] [Abstract][Full Text] [Related]
14. Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. Desai AS; Liu J; Pfeffer MA; Claggett B; Fleg J; Lewis EF; McKinlay S; O'Meara E; Shah SJ; Sweitzer NK; Solomon S; Pitt B J Card Fail; 2018 May; 24(5):313-320. PubMed ID: 29572190 [TBL] [Abstract][Full Text] [Related]
15. Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapy. Maeder MT; Rickli H; Pfisterer ME; Muzzarelli S; Ammann P; Fehr T; Hack D; Weilenmann D; Dieterle T; Kiencke S; Estlinbaum W; Brunner-La Rocca HP; Am Heart J; 2012 Mar; 163(3):407-14, 414.e1. PubMed ID: 22424011 [TBL] [Abstract][Full Text] [Related]
16. Impact of worsening renal function related to medication in heart failure. Brunner-La Rocca HP; Knackstedt C; Eurlings L; Rolny V; Krause F; Pfisterer ME; Tobler D; Rickenbacher P; Maeder MT; Eur J Heart Fail; 2015 Feb; 17(2):159-68. PubMed ID: 25808849 [TBL] [Abstract][Full Text] [Related]
17. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial. Ravassa S; Trippel T; Bach D; Bachran D; González A; López B; Wachter R; Hasenfuss G; Delles C; Dominiczak AF; Pieske B; Díez J; Edelmann F Eur J Heart Fail; 2018 Sep; 20(9):1290-1299. PubMed ID: 29709099 [TBL] [Abstract][Full Text] [Related]
18. [Efficacy and safety of long-term application of spironolactone in patients with moderate and severe chronic heart failure receiving optimal therapy]. Skvortsov AA; Mareev VY; Chelmakina SM; Baklanova NA; Belenkov IuN Kardiologiia; 2007; 47(10):12-23. PubMed ID: 18260939 [TBL] [Abstract][Full Text] [Related]
19. Diuretic and renal effects of spironolactone and heart failure hospitalizations: a TOPCAT Americas analysis. Kalogeropoulos AP; Thankachen J; Butler J; Fang JC Eur J Heart Fail; 2020 Sep; 22(9):1600-1610. PubMed ID: 32469156 [TBL] [Abstract][Full Text] [Related]
20. Increased Spironolactone Dosing in Acute Heart Failure Alters Potassium Homeostasis but Does not Enhance Decongestion. Natov PS; Ivey-Miranda JB; Cox ZL; Rao VS; Butler J; Konstam MA; Kiernan MS; Kapur NK; Testani JM J Card Fail; 2024 Nov; 30(11):1522-1526. PubMed ID: 38986838 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]